Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 601–657 of 657
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Self-citationMosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Self-citationDang, L. E. (2023) · eScholarship (California Digital Library)
Semaglutide Affecting Alcohol Consumption
Chandrasekara, L., Han, J., & Arasu, A. (2024) · eScholarship (California Digital Library)
Qual o impacto da terapêutica farmacológica na perda de peso em doentes com excesso de peso?
Medeiros, D. M. A. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Lourenço, D. L. D. S. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/3f3f-0z07
Sá, A. I. G. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/5nfc-ce41
Šljivić, M., Jašić, M., Bajrić, M., Hodzic, J., Jusić, D., Šubarić, D., Aleksovski, A., & Divković, A. (2025) · University of Zagreb University Computing Centre (SRCE)
Long-Term Adverse Effects of Semaglutide Use: A Systematic Review
de Souza, E. M., & Sabattini, A. C. (2025) · doi:10.62486/978-9915-704-12-8.ch21
Antsiferova, D. M., Ametov, A. S., Koteshkova, O. M. K., Ромашкина, Л. П., & Antsiferov, M. B. (2026) · Diabetes Mellitus · doi:10.14341/dm13441
Terasaki, M., Zhou, Q., Andersson, O., & Yamagishi, S.-I. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0214
Saldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
2型糖尿病患者におけるリラグルチドまたはデュラグルチドからセマグルチド皮下投与への切り替えによる血糖コントロールと治療満足度の改善:多施設共同前向き無作為化非盲検並行群間比較試験
髙橋, 由. (2024) · Institutional Repositories DataBase (IRDB) · doi:10.14943/doctoral.k15901
Zaccardi, F., Aroda, V. R., Arslan, E. G., Bardtrum, L., Goldney, J., Ising, E., Priyadarshini, P., Slater, T., & Davies, M. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70770
Self-citationKhanna, A., Kumar, V., & Gola, S. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_686_25
Jahić, M., & Matić, N. (2026) · UniCath journal of biomedicine and bioethics · doi:10.64332/ujbb.3.1.7
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Sümbül, H. E., Işık, B., Mustan, A. G., Alişan, İ., Erhan, Ç., Koca, F. I., Uçar, A., Erdevir, M., Avcı, B. Ş., Sumbul, M. S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114105
Biyabani, S. A. U., Patil, N., Fatima, Z., Salimath, P. V., Babladi, V. P., & Naema, H. (2026) · Journal of Pharma Insights and Research. · doi:10.69613/ss2yp015
Fasinu, P. S., Coric, T., & Wilborn, T. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00458-9
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Yin, Y., Ma, J. H., Liu, D., Duan, W., Cheng, Z., Jiang, H. X., Zhang, Y., Wu, G., Zhuang, H., Gu, W., et al. (2026) · Med · doi:10.1016/j.medj.2026.101183
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
The application of GLP-1 receptor agonists in obesity due to MC4R deficiency
Ding, M., Luo, Y., & Ji, L. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.58
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
As, A., Балыкова, Л. А., Zaslavskaya, K. Y., Shohin, I. E., Геннадьевна, Б. Т., Zorina, L. A., Shcherbakova, V. S., Куркин, Д. В., Koryanova, K. N., Mishchenko, E. S., et al. (2026) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2026-14-4-387-409
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Rodbard, H. W., Irace, C., Lobo, J., Makrilakis, K., Priyadarshini, P., Sivalingam, S., Tofé, S., & Bhargava, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71132
Dizdarević-Bostandžić, A., Hadzigrahic, E., & Nišić, A. (2026) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2026-001616
Thandampallayam, M., Abusamra, K., Kini, T. A., & Vasireddy, R. P. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1125_25
Ambrish, C., Lila, A. R., Parikh, A., Mangipudi, A., Sonawane, A., Kiran, B. H., Das, B., Chopde, C., Varade, D., Madhusudan, C., et al. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100489
Djatmiko, N. I., Asyhar, M. L., Alridjal, R., Faradila, Z., Sholihah, F. H., Santoso, B. V., Kusuma, M. A. S., & Sanjaya, C. (2026) · The Indonesian Journal of General Medicine · doi:10.70070/bbvjb653
Translational Advances in GLP-1–Based Therapies for Cardiometabolic Disease
Yadav, S. K., Yadav, N. K., Yadav, K., & Shekh, M. (2026) · Journal of Integrative and Translational Biomedicine · doi:10.67316/jintb.v1.i3.21
Bawadi, H. A., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70338
Semaglutide: A Tool to Empower Indian Women Against the Twin Challenges of Diabetes and Weight
Lathia, T. B., Beatrice, A., George, B., & Maisnam, I. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_44_26
Wang, S., DONG, B., & Shen, Z. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01915-y
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Khurshid, B., & Khurshid, S. (2025) · Review journal of neurological & medical sciences review. · doi:10.63075/w16p9p55
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · JMIR Public Health and Surveillance · doi:10.2196/99738
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Сергеевич, А. А., Александровна, Б. Л., Яковлевна, З. К., Евгеньевич, Ш. И., Геннадьевна, Б. Т., Анатольевна, З. Л., Сергеевна, Щ. В., Владимирович, К. Д., Koryanova, K. N., Сергеевна, М. Е., et al. (2026) · Pharmacy & Pharmacology
Stüdemann, S., Gollasch, M., & Engeli, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786211
Gędek, A., Modrzejewski, S., Polański, K., Waśniewska, L., Molero, P., Wichniak, A., Dominiak, M., & McIntyre, R. S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113886
Валерьевна, Т. Е., Викторовна, З. Е., Леонидович, В. Д., Евгеньевна, М. В., Владимировна, Ф. О., Razzhivina, V., Крылова, Н. В., Игоревна, П. А., Васильевна, П. А., Сергеевич, В. А., et al. (2026) · Endocrinology News Opinions Training
Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
Ali, M. A., Das, S., Kumar, R. R., & Rabindra, K. (2026) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/26oct881
Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
Bovee, L. B., & Thirumalai, A. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00469-y
Wu, D., Yang, R., Zeng, J., Bai, Z., Zhang, C., Fan, X., Zhou, X., Wu, L., Zhu, S., Akın, İ., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-06025-x
Yue, D., Xu, B., Lai, H., Qian, Y., Guo, J., Zhou, D., Shen, B., & Zha, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981282
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · doi:10.3389/fphar.2022.935823.s001
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.